Company profile: Dewpoint Therapeutics
1.1 - Company Overview
Company description
- Provider of condensate-modifying drugs and an AI-powered drug discovery platform focused on biomolecular condensates. Offers therapies targeting TDP-43 for ALS and neurodegenerative diseases and beta catenin for cancers such as colorectal cancer. Engages in partnerships with pharmaceutical companies to develop drugs for cardiovascular diseases, insulin resistance, and oncology.
Products and services
- AI-powered drug discovery platform: Computationally-driven platform integrates AI with experimental technologies to develop drugs targeting biomolecular condensates, supporting condensate-focused discovery programs across disease areas
- Condensate-modifying drugs (c-mods): Custom-engineered therapeutics that target and modulate biomolecular condensates to treat diseases such as ALS, cancer, and other conditions
- TDP-43 targeted therapies: ALS-focused therapeutics that modulate TDP-43 condensates to treat ALS and potentially other neurodegenerative diseases through condensate-targeted intervention
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Dewpoint Therapeutics
BrainBox Solutions
HQ: United States
Website
- Description: Provider of objective evidence of injury and prediction of patient recovery.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full BrainBox Solutions company profile →
CC Bio
HQ: United Kingdom
Website
- Description: Provider of microbiome-focused therapeutic discovery for diagnosis and treatment. Products include Zeus, a platform to evaluate and optimize therapeutics for precise augmentation of microbial ecology; Athena, a platform developing genetic components for biosensor circuits that sense microbiome diseases; and Dionysus, a program engineering bacterial chassis to sense metabolic changes and record information across human tissues.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full CC Bio company profile →
Trinean
HQ: Belgium
Website
- Description: Provider of micro-volume molecular spectroscopy solutions, combining best-in-class analytical software with a highly standardized read-out platform; commercializes UV/VIS spectrometers.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Trinean company profile →
Multi Channel Systems
HQ: Germany
Website
- Description: Provider of precise electrophysiology measuring instrumentation and software for research groups at universities, including microelectrode arrays (Mesh MEA) and systems combining laser-based optoporation with MEAs for intracellular action potential recordings in cardiac monolayers and organoids, plus data acquisition, analysis and screening tools (Multi Channel Suite, Multiwell-Screen, CMOS-MEA-Control, Beta-Screen Experimenter).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Multi Channel Systems company profile →
Anterios
HQ: United States
Website
- Description: Provider of botulinum-based prescription products for aesthetic medicine and dermatology and nanotechnology-based delivery systems for administering drugs and cosmetics.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Anterios company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Dewpoint Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Dewpoint Therapeutics
2.2 - Growth funds investing in similar companies to Dewpoint Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Dewpoint Therapeutics
4.2 - Public trading comparable groups for Dewpoint Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →